Ace the ISMPP Publication Primer 2026 – Publish Your Way to Success!

The correct answer indicates that summary results information must be reported no later than 1 year after trial completion due to the requirements set forth by the FDA Amendments Act (FDAA). This regulation was established to ensure transparency and public access to clinical trial data, thereby facilitating informed decisions by healthcare professionals and patients alike.

Reporting within this timeframe allows the FDA and the public to have timely access to essential information that evaluates the safety and efficacy of medical products. It is crucial for accountability in clinical research, promoting ethical standards, and ensuring that results are not withheld.

While some might suggest more immediate timelines, the one-year requirement strikes a balance between allowing researchers adequate time to compile and review results while still prioritizing public access to vital health information. This timeframe helps to prevent any significant delays in transparency and can support ongoing scientific inquiry and patient safety.